Navigation Links
IDM Pharma Reports 2007 Financial Results
Date:3/20/2008

IRVINE, Calif., March 20 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today reported financial results for the fourth quarter and full year ended December 31, 2007. Financial information presented represents the consolidated results of IDM Pharma, Inc. and its subsidiary, IDM Pharma S.A.

Total revenues in the quarter ended December 31, 2007 were $5.6 million, and net loss was $2.7 million or $0.11 per share for the quarter. Total revenues for the year ended December 31, 2007 were $14.6 million, and net loss was $18.3 million or $0.87 per share for the year. Revenues in both the quarter and year ended December 31, 2007 included $2.4 million of deferred revenue recognized by the Company as a result of the decision by sanofi-aventis to terminate its participation in the UVIDEM development program in December 2007. Cash and cash equivalents was $28.4 million as of December 31, 2007 compared to $33.2 million on September 30, 2007 and $10.2 million on December 31, 2006. We believe that our existing cash resources are sufficient to meet our cash requirements, based on our current development and operating plan, into the first half of 2009.

Business Highlights

-- The European Committee for Medicinal Products for Human Use, or CHMP,

determined in a non-binding opinion in late January 2008 that

L-MTP-PE suggested a possible clinical benefit in terms of survival

and granted the Company a clock stop, or time extension.

-- The Company expects to receive a final opinion regarding L-MTP-PE from

the CHMP in the third quarter of 2008 and a final decision from the

European Commission in the fourth quarter of 2008.

-- The Company expects to file an amendment to the L-MTP-PE new drug

application, or NDA, to the FDA in the fourth quarter of 2008.

-- Updated Phase 3 data on L-MTP-PE was presented at the Connective

Tissue Oncology Society, or CTOS, meeting in November 2007. Also,

data from our L-MTP-PE compassionate use program was presented at the

November 2007 meeting of the International Society of Pediatric

Oncology, or SIOP.

-- Announced Phase 3 Mifamurtide (L-MTP-PE) study demonstrating improved

survival was published in the Journal of Clinical Oncology in February

2008. Children's Oncology Group report shows the addition of L-MTP-PE

to chemotherapy reduced the risk of death by 30% in osteosarcoma

patients.

-- In June 2007, we completed a registered direct offering of our common

stock, and warrants to purchase common stock, and received

approximately $25.0 million in gross proceeds, and finished 2007 with

$28.4 million, providing cash for operations into the first half of

2009.

"We made significant progress over the past year in our efforts to bring our lead product candidate, L-MTP-PE, to market in Europe," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We are developing L-MTP-PE for the treatment of osteosarcoma, the most common type of bone cancer affecting adolescents. We believe our updated survival data from the L-MTP-PE Phase 3 trial, demonstrating statistically superior overall survival in long-term patient follow-up, were critical to the recent non-binding opinion of the Committee for Medicinal Products for Human Use in Europe that L-MTP-PE suggested a possible clinical benefit in terms of survival. We remain committed to resolving the remaining items of the L-MTP-PE European Marketing Authorization Application and working at the same time to advance this important potential treatment through its U.S. regulatory path."

Details of Financial Results

Total revenues in the quarter ended December 31, 2007 were $5.6 million compared to total revenues of $3.0 million for the quarter ended December 31, 2006. Total revenues were $14.6 million for the year ended December 31, 2007, compared to total revenues of $11.3 million for the year ended December 31, 2006. Revenues in all periods were primarily in connection with the Company's collaboration agreement with sanofi-aventis.

Research and development (R&D) expenses in the quarter ended December 31, 2007 decreased to $4.8 million from $5.3 million in the prior year period. For the year ended December 31, 2007, R&D expenses decreased to $21.8 million for the year ended December 31, 2007 from $22.3 million in 2006. Increased R&D spending during the periods related to L-MTP-PE and UVIDEM development was offset by reductions in development activities related to IDM-2101 and other development candidates that the Company has put on hold, as well as reductions associated with lower headcount and termination of a lease agreement for certain of the Company's Paris facilities.

Selling and marketing and general and administrative (SG&A) expenses were $2.9 million for the quarter ended December 31, 2007 compared with $2.8 million in the prior year period. SG&A expenses increased to $12.6 million for the year ended December 31, 2007 from $10.0 million for the year ended December 31, 2006. The higher expenses in 2007 include $0.5 million in fees paid to an investment advisor in connection with the private placement completed in February 2007, $1.1 million associated with accrued severance benefits, $0.5 million in bonus accruals, and $0.4 million due to higher headcounts and consultant costs in the sales and marketing area.

Restructuring expenses were $1.1 million for both the quarter and year ended December 31, 2007, which included $0.5 million of severance benefits and $0.6 million of fixed asset impairments related to the decision to close the Company's operations in France following notification of sanofi-aventis' decision in December 2007 to terminate its participation in the UVIDEM development program.

Interest income increased to $0.4 million for the three months ended December 31, 2007 from $0.1 million in the prior year period. Interest income increased to $1.1 million for the year ended December 31, 2007 from $0.5 million in 2006. These increases in interest income were the result of higher investment cash balances.

Interest expense for the quarter ended December 31, 2007 was a negative expense of $1.1 million compared with no interest expense in the prior year period. Interest expense for the year ended December 31, 2007 was a negative expense of $3.9 million compared to no interest expense for the year ended December 31, 2006. The negative expense in both the quarter and year ended December 31, 2007 was to record the net decrease in the fair value of warrants issued in February and June 2007.

The foreign exchange loss, which results from changes in the value of the dollar versus the Euro on the dollar denominated inter-company loan between the Company's subsidiaries, was $0.4 million in the fourth quarter of 2007, compared to $0.9 million in the prior year period. This foreign exchange loss was $1.7 million in the year ended December 31, 2007, compared to $2.6 million in 2006.

Net loss for the fourth quarter of 2007 was $2.7 million, or $0.11 per basic and diluted share, compared to a net loss of $5.9 million, or $0.44 per share in the corresponding period in 2006. Net loss for the year ended December 31, 2007 was $18.3 million, or $0.87 per basic and diluted loss per share compared to a net loss of $23.5 million, or $1.75 per share in the year ended December 31, 2006.

Update on L-MTP-PE Regulatory Status

The Company recently announced that following presentation of data at an oral explanation hearing before the Committee for Medicinal Products for Human Use (CHMP), the CHMP determined in a non-binding opinion that L-MTP-PE suggested a possible clinical benefit in terms of survival and granted the Company a clock stop, or time extension. The clock stop will allow the Company additional time to respond to all the remaining questions regarding the marketing authorization application for L-MTP-PE (MAA). The CHMP has requested clarification of the existing data in order to gain assurance about the quality of the data before drawing any final conclusions from the data presented. In addition, the Company is required to address a number of remaining questions relating to chemistry, manufacturing and controls (CMC). The Company expects to receive a final opinion from the CHMP in the third quarter and a final decision from the European Commission in the fourth quarter of 2008.

As previously announced, in the United States the Company continues to work with the Children's Oncology Group as well as external experts and advisors to gather patient follow up data from the Phase 3 clinical trial of L-MTP-PE and to respond to other questions in the non-approvable letter the Company received from the U.S. Food and Drug Administration (FDA). The Company expects to submit the amended new drug application (NDA) in the fourth quarter of 2008.

L-MTP-PE was granted orphan drug status in the United States in 2001 and in Europe in 2004. In Europe, the MAA was filed in November 2006 and in the U.S., the NDA was submitted to FDA in October 2006 and was accepted for review in December 2006.

As previously announced, the Company is evaluating the Company's research and development programs, including related assets and costs, and strategic alternatives available to the Company.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the timeframe in which the Company's cash will be sufficient to meet planned operations, the Company's plans to address the remaining questions with respect to the MAA during the clock-stop granted by the CHMP, and the expected timing of a final opinion from the CHMP and of a final regulatory decision regarding the MAA in the European Union, as well as the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE, including the expected timing for such amended NDA, and to respond to other matters raised by the FDA and plans to evaluate strategic alternatives. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to provide assurance regarding the quality of the existing data and to respond to the remaining issues with regard to the MAA, including verification of data quality and CMC items, to the satisfaction of the CHMP, whether the final opinion of the CHMP will be consistent with the non-binding opinion of the CHMP, whether the European Commission will follow the final opinion of the CHMP once issued, whether the timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that additional data from the Phase 3 clinical trial of L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE submitted by the Company may not provide adequate support for regulatory approval of L-MTP-PE in the United States within the timeframe expected by the Company, if at all, whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities, and whether the cash resources of the Company will be sufficient to fund operations as planned. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended September 30, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

IDM PHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)

Twelve Months

Quarter Ended December 31, Ended December 31,

2007 2006 2007 2006

Revenues:

Related party

revenue $5,252,000 $2,919,000 $14,246,000 $11,147,000

Research grants and

contract revenue - 28,000 55,000 96,000

License fees,

milestones and

other revenues 299,000 11,000 329,000 43,000

Total revenues 5,551,000 2,958,000 14,630,000 11,286,000

Costs and expenses:

Research and

development 4,796,000 5,297,000 21,828,000 22,329,000

Impairment of

patents and

licenses 416,000 95,000 511,000 592,000

Selling and

marketing 576,000 208,000 1,024,000 605,000

General and

administrative 2,319,000 2,585,000 11,535,000 9,402,000

Restructuring 1,092,000 - 1,092,000 -

Total costs and

expenses 9,199,000 8,185,000 35,990,000 32,928,000

Loss from

operations (3,648,000) (5,227,000) (21,360,000) (21,642,000)

Interest income 360,000 76,000 1,118,000 503,000

Interest expense 1,053,000 - 3,878,000 -

Other income, net 23,000 - - -

Foreign exchange

loss (381,000) (861,000) (1,680,000) (2,559,000)

Loss before income

tax (2,593,000) (6,012,000) (18,044,000) (23,698,000)

Income tax (expense)

benefit (89,000) 64,000 (306,000) 243,000

Net loss $(2,682,000) $(5,948,000) $(18,350,000) $(23,455,000)

Weighted average

number of shares

outstanding 25,148,380 13,401,071 21,075,738 13,366,002

Basic and diluted

loss per share $(0.11) $(0.44) $(0.87) $(1.75)

Comprehensive loss:

Net loss $(2,682,000) $(5,948,000) $(18,350,000) $(23,455,000)

Other comprehensive

gain 403,000 1,157,000 2,041,000 3,545,000

$(2,279,000) $(4,791,000) $(16,309,000) $(19,910,000)

IDM PHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

December 31, December 31,

2007 2006

ASSETS

Current assets:

Cash and cash equivalents $28,382,000 $10,181,000

Other current assets 4,786,000 4,973,000

Total current assets 33,168,000 15,154,000

Property and equipment, net 513,000 1,711,000

Patents, trademarks and other licenses, net 2,734,000 3,323,000

Goodwill 2,812,000 2,812,000

Other long-term assets 832,000 1,382,000

Total Assets $40,059,000 $24,382,000

LIABILITIES AND STOCKHOLDERS' EQUITY

Common stock warrants $450,000 $-

Other current liabilities 11,712,000 10,636,000

Other liabilities 1,874,000 3,550,000

Stockholders' equity 26,023,000 10,196,000

Total liabilities and stockholders'

equity $40,059,000 $24,382,000


'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. ... “Those who don’t learn from history are doomed to repeat it.” , An analysis of ... year. But that takes time. , Take a close look at the warning letters ...
(Date:2/12/2016)... ... , ... As a former television executive, owner Tal Rabinowitz knows how stressful ... decompress, Rabinowitz found herself drawn to a casual meditation class while working at NBC ... implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, she ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for ... General Hospital on April 5-7. The series is a multi-day, multi-workshop event designed ... workshops cover a broad range of topics, including coaching skills, the scientific method ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO ... Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern ... Nevada Healthcare System. This will be the first Fisher House in Nevada, and ...
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, ... in 2016 . The list consists of physicians establishing, leading and partnering with ambulatory ... , An Ambulatory Surgery Center, also known as an ASC, is a modern ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , February 12, 2016 /PRNewswire/ ... nicht anders vermerkt)   http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... des Unternehmens http://www.telestatherapeutics.com abrufbar.    ... (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss des ...
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... 2016 On Thursday, Feb. 11, 2016, surgeons ... David,s North Austin Medical Center successfully completed the first ... ® Surgical System with Trumpf Medical,s advanced operating ... Lakshman , M.D., colorectal surgeon at the Texas Institute ... Table Motion technology, which seamlessly combines the da Vinci ...
Breaking Medicine Technology: